SEC Form 4/A · accession 0001562180-16-003577
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Theodore Alan Huizenga
Officer — Controller and PAO
Period of report
Jun 17, 2015
Accepted (ET)
Nov 18, 2016 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 17, 2015 | M | 1,500 | $21.00 | A | 5,800 | D | |
| Common StockF2,F1 | Jun 17, 2015 | S | 1,500 | $94.80 | D | 4,300 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Due to a clerical error, the number of shares beneficially owned following the reported transaction mistakenly excluded 1,800 shares owned by the Reporting Person. These 1,800 shares were also omitted from five Forms 4 filed by the Reporting Person after this Form 4 was filed.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.76 to $94.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.